Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)

Inclusion Criteria: * 12 years or older * nodules and papules consistent with post kala-azar dermal leishmaniasis * parasitological confirmation of Leishmania infection Exclusion Criteria: * platelet count \<100x 109/l, * leukocyte count \<2.5 x 109/l , * hemoglobin \< 8.0 g/100 ml , * liver function tests \>3 times upper limit of normal range, * bilirubin \>2 times upper limit of normal range, * serum creatinine or blood urea nitrogen \>1.5 times upper limit of normal range); * any non-compensated or uncontrolled condition, * lactation, pregnancy, or likelihood of inadequate contraception in females of childbearing potential for the treatment period plus 2 months thereafter; * treatment with any anti-leishmanial drug within the previous 12 weeks.